AP-HP, Groupement Hospitalier Pitié-Salpêtrière, E3M Institute, Internal Medicine Department 2, National Reference Centre for Systemic Lupus Erythematosus, F-75013, Paris, France.
AP-HP, Groupement Hospitalier Pitié-Salpêtrière, E3M Institute, Internal Medicine Department 2, National Reference Centre for Systemic Lupus Erythematosus, F-75013, Paris, France; Inserm, U1135, CIMI, F-75013, Paris, France; Sorbonne Universités, UPMC Univ Paris 06, F-75013, Paris, France.
Autoimmun Rev. 2014 Jul;13(7):730-5. doi: 10.1016/j.autrev.2014.03.001. Epub 2014 Mar 20.
Conflicting data have been published regarding the risk of cervical lesions among women with systemic lupus erythematosus (SLE). We systematically reviewed the evidence for an association of SLE with cervical precancerous lesions (high-grade squamous intraepithelial lesions, HSIL), and performed a meta-analysis to determine the risk of HSIL in SLE patients. Observational studies identified up to February 2013 from the Medline, Embase and Cochrane databases were selected if they assessed the prevalence of HSIL in female SLE patients versus healthy female controls and included in a meta-analysis with pooled effect estimates obtained using a random-effects model. Of 235 citations retrieved, 7 studies met inclusion criteria. The pooled odds ratio for the risk of HSIL in SLE patients (n=416) versus female controls (n=11,408) was 8.66 (95% CI: 3.75-20.00), without significant heterogeneity across studies. Cumulative meta-analysis according to year of study publication revealed a slight increase in the risk of HSIL in the 2001-2011 period and then a stabilization afterwards. This meta-analysis shows that the risk of HSIL is significantly increased in SLE patients, compared to healthy female controls. This suggests that women with SLE may benefit from HPV vaccines and specific cervical cancer screening.
关于系统性红斑狼疮(SLE)女性宫颈病变的风险,已有相互矛盾的数据发表。我们系统地回顾了 SLE 与宫颈前病变(高级别鳞状上皮内病变,HSIL)相关的证据,并进行了荟萃分析,以确定 SLE 患者发生 HSIL 的风险。如果观察性研究评估了女性 SLE 患者与健康女性对照者中 HSIL 的患病率,并使用随机效应模型获得汇总效应估计值纳入荟萃分析,则可选择截至 2013 年 2 月从 Medline、Embase 和 Cochrane 数据库中检索到的研究。从 235 条引文检索中,有 7 项研究符合纳入标准。SLE 患者(n=416)与女性对照者(n=11408)发生 HSIL 的风险的汇总优势比为 8.66(95%CI:3.75-20.00),各研究间无显著异质性。根据研究发表年份的累积荟萃分析显示,2001-2011 年期间 HSIL 的风险略有增加,之后稳定下来。这项荟萃分析表明,与健康女性对照者相比,SLE 患者发生 HSIL 的风险显著增加。这表明 SLE 女性可能受益于 HPV 疫苗和特定的宫颈癌筛查。